Suboptimal analysis using 'optimal' cutpoints.
作者信息
Altman D G
出版信息
Br J Cancer. 1998 Aug;78(4):556-7. doi: 10.1038/bjc.1998.537.
Abstract
摘要
相似文献
1
Suboptimal analysis using 'optimal' cutpoints.使用“最佳”切点进行的次优分析。
Br J Cancer. 1998 Aug;78(4):556-7. doi: 10.1038/bjc.1998.537.
2
On the problem of using 'optimal' cutpoints in the assessment of quantitative prognostic factors.关于在定量预后因素评估中使用“最佳”切点的问题。
Onkologie. 2001 Apr;24(2):194-9. doi: 10.1159/000050315.
3
Re: "The inconsistency of 'optimal' cutpoints obtained using two criteria based on the receiver operating characteristic curve".关于：“使用基于接收者操作特征曲线的两个标准获得的‘最佳’切点的不一致性”。
Am J Epidemiol. 2006 Oct 1;164(7):707-8; author reply 708. doi: 10.1093/aje/kwj292. Epub 2006 Aug 17.
4
A solution for the most basic optimization problem associated with an ROC curve.与ROC曲线相关的最基本优化问题的一种解决方案。
Stat Methods Med Res. 2006 Dec;15(6):571-84. doi: 10.1177/0962280206070637.
5
Validation of surrogate end points for overall survival in advanced colorectal cancer: further need for clarification: Letter to the editor on: Ciani et al., 2015, Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. 2015, J Clin Epidemiol 68:833-842.晚期结直肠癌总生存替代终点的验证：仍需进一步阐明：致编辑的信，关于：西亚尼等人，2015年，随机对照试验的荟萃分析显示晚期结直肠癌总生存替代结局的有效性欠佳。2015年，《临床流行病学杂志》68:833 - 842。
J Clin Epidemiol. 2016 Feb;70:278-9. doi: 10.1016/j.jclinepi.2015.08.019. Epub 2015 Sep 5.
6
Strategies for developing Ki67 as a useful biomarker in breast cancer.将Ki67开发为乳腺癌有用生物标志物的策略。
Breast. 2015 Nov;24 Suppl 2:S67-72. doi: 10.1016/j.breast.2015.07.017. Epub 2015 Aug 14.
7
[Minimal residual disease in acute leukemias. Optimal method of detection].
Pol Arch Med Wewn. 1996 Jun;95(6):585-94.
8
Cardiovascular disease and vitamins. Concurrent correction of 'suboptimal' plasma antioxidant levels may, as important part of 'optimal' nutrition, help to prevent early stages of cardiovascular disease and cancer, respectively.心血管疾病与维生素。作为“最佳”营养的重要组成部分，同时纠正“次优”的血浆抗氧化剂水平可能分别有助于预防心血管疾病和癌症的早期阶段。
Bibl Nutr Dieta. 1995(52):75-91.
9
'Optimal' participation: a reflective look.“最佳”参与：反思审视
Disabil Rehabil. 2006 Oct 15;28(19):1231-5. doi: 10.1080/09638280600554827.
10
The highs and lows of tumor biomarkers: lost illusions.
Clin Chem Lab Med. 2015 Feb;53(3):343-7. doi: 10.1515/cclm-2015-0014.
引用本文的文献
1
Multi-Quantitative Assessment of AS-OCTA Complemented AS-OCT for Monitoring Filtering Bleb Function After Trabeculectomy.多定量评估 AS-OCTA 联合 AS-OCT 监测小梁切除术后滤过泡功能
Transl Vis Sci Technol. 2023 Jul 3;12(7):18. doi: 10.1167/tvst.12.7.18.
2
Optimal partitioning for the proportional hazards model.比例风险模型的最优分割
J Appl Stat. 2020 Nov 18;49(4):968-987. doi: 10.1080/02664763.2020.1846690. eCollection 2022.
3
ITGB4 is a novel prognostic factor in colon cancer.整合素β4（ITGB4）是结肠癌的一种新的预后因素。
J Cancer. 2019 Aug 28;10(21):5223-5233. doi: 10.7150/jca.29269. eCollection 2019.
4
Integrative analyses of transcriptome sequencing identify novel functional lncRNAs in esophageal squamous cell carcinoma.转录组测序的综合分析鉴定出食管鳞状细胞癌中的新型功能性长链非编码RNA。
Oncogenesis. 2017 Feb 13;6(2):e297. doi: 10.1038/oncsis.2017.1.
5
Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer.激肽释放酶相关肽酶13：非小细胞肺癌患者预后良好的独立指标。
Tumour Biol. 2015 Jul;36(7):4979-86. doi: 10.1007/s13277-015-3148-1. Epub 2015 Feb 13.
6
Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer -what has gone wrong? A blueprint for the way forward in biomarker studies.前列腺癌已发表的免疫组化预后生物标志物的全面验证——哪里出了问题？生物标志物研究前进方向的蓝图。
Br J Cancer. 2015 Jan 6;112(1):140-8. doi: 10.1038/bjc.2014.588. Epub 2014 Nov 25.
7
Publication of tumor marker research results: the necessity for complete and transparent reporting.肿瘤标志物研究结果的发表：完整和透明报告的必要性。
J Clin Oncol. 2012 Dec 1;30(34):4223-32. doi: 10.1200/JCO.2012.42.6858. Epub 2012 Oct 15.
8
Regression calibration for dichotomized mismeasured predictors.二分法测量错误预测变量的回归校准
Int J Biostat. 2009;5(1):Article 12. doi: 10.2202/1557-4679.1143.
9
Survival analysis part IV: further concepts and methods in survival analysis.生存分析第四部分：生存分析中的进一步概念与方法。
Br J Cancer. 2003 Sep 1;89(5):781-6. doi: 10.1038/sj.bjc.6601117.
本文引用的文献
1
Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis.组织蛋白酶-D含量与淋巴结阴性乳腺癌患者无病生存率的关系：一项荟萃分析。
Br J Cancer. 1997;76(5):661-6. doi: 10.1038/bjc.1997.442.
2
Flow cytometric S-phase fraction in soft-tissue sarcoma: prognostic importance analysed in 160 patients.软组织肉瘤的流式细胞术S期分数：对160例患者的预后重要性进行分析
Br J Cancer. 1997;75(1):94-100. doi: 10.1038/bjc.1997.15.
3
A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis.单变量生存分析中用于选择最优切点的交叉验证模拟研究。
Stat Med. 1996 Oct 30;15(20):2203-13. doi: 10.1002/(SICI)1097-0258(19961030)15:20<2203::AID-SIM357>3.0.CO;2-G.
4
Statistical aspects of prognostic factor studies in oncology.肿瘤学中预后因素研究的统计学方面。
Br J Cancer. 1994 Jun;69(6):979-85. doi: 10.1038/bjc.1994.192.
5
Dangers of using "optimal" cutpoints in the evaluation of prognostic factors.在评估预后因素时使用“最佳”切点的风险。
J Natl Cancer Inst. 1994 Jun 1;86(11):829-35. doi: 10.1093/jnci/86.11.829.
6
Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer.通过蛋白质免疫印迹法和免疫组织化学检测组织蛋白酶D：未能证实其与淋巴结阴性乳腺癌预后的相关性
J Clin Oncol. 1994 Mar;12(3):467-74. doi: 10.1200/JCO.1994.12.3.467.
7
Review of survival analyses published in cancer journals.对发表在癌症期刊上的生存分析的综述。
Br J Cancer. 1995 Aug;72(2):511-8. doi: 10.1038/bjc.1995.364.
8
Why do so many prognostic factors fail to pan out?为什么这么多预后因素最终都未成功？
Breast Cancer Res Treat. 1992;22(3):197-206. doi: 10.1007/BF01840833.
Zotero 插件